Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 812 results for "sanofi country"

First dengue vaccine may be available in H2 2015: Sanofi
Money Control

First dengue vaccine may be available in H2 2015: Sanofi

The French drugmaker's Sanofi Pasteur division intends to file for registration for the vaccine in several endemic countries next year, it said in a statement. Money Control, 2 months ago
Sanofi launches Shan5 paediatric pentavalent vaccine The Financial Chronicle, 2 months ago
Vaccine for dengue in 2015: Sanofi Pasteur Asian Age, 2 months ago
[x]  
Pharma Letter

Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog

The European Commission (EC) has approved Sanofi 's ( SNY ) first line oral therapy, Cerdelga, for the treatment of certain adults suffering from Gaucher disease type I. The company said that adults who metabolize Cerdelga more rapidly or at an ...
 Zacks.com2 days ago Update: Sanofi Wins EC Marketing Authorization For Cerdelga  Seeking Alpha2 days ago Genzyme receives marketing authorization from EC for Gaucher disease drug  Individual.com2 days ago Sanofi SA (SNY) Gaucher Disease Drug Cerdelga Wins EU Approval  Bidness Etc2 days ago
[x]  
Macau Daily Times

Glaxo, Pfizer Blamed for High Prices on Vaccines in Poor Nations

GlaxoSmithKline Plc (GSK) and Pfizer Inc. (PFE) are overcharging for vaccines in developing countries , Doctors Without Borders said, leaving some nations unable to afford shots that reduce child mortality. Lack of transparency and scant ...
 Bloomberg5 days ago Pharmaceuticals | Glaxo, Pfizer blamed for high prices on vaccines in poor nations  Macau Daily Times4 days ago GlaxoSmithKline, Pfizer blamed for high vaccine prices  Livemint.com5 days ago Glaxo, Pfizer Blamed for High Vaccine Prices in Poor Nations  Washington Post5 days ago

Sanofi: European Commission Approves Merial's NexGard Spectra - Quick Facts

Sanofi (SNYNF: Quote,SNY: Quote) and its animal health company Merial announced that the European Commission has approved NexGard Spectra, a soft, beef-flavored chew for dogs that provides a broad spectrum of internal and external parasite control ...
 RTTNews.com6 days ago SANOFI : Merial receives European approval for chewable NexGard® Spectra(TM)  4 Traders6 days ago Press Release: SANOFI : Merial receives European approval for chewable NexGard(R) Spectra(TM)  iMarketReports6 days ago REG-SANOFI : Merial receives European approval for chewable NexGard(R) Spectra(TM)  Reuters6 days ago
Boston Globe

From an uncertain process of guesses and science, each year's flu vaccines emerge

WASHINGTON — In early March, Dr. Robert Daum and other infectious-disease specialists from around the country will gather in a Silver Spring, Md., hotel to choose the influenza strains that vaccine makers should target for next year's flu season. ...
 Boston Globe1 week ago Scientists guessed wrong on the flu vaccine. It could happen again.  Washington Post2 weeks ago Why scientists guessed wrong on this year's flu vaccine, and why it could happen again  Washington Post2 weeks ago

Across the country, flu takes toll on elderly

Senior citizens in nursing homes, assisted-living facilities and hospitals across the country are being slammed with the flu this year thanks in part to a vaccine that failed to offer strong protection from the virus and a strain that's particularly ...
 USA Today1 week ago

Are the people really sharing in the country's wealth?

Sixty years after it was drafted, the Freedom Charter has again taken centre stage with rival political parties claiming its principles ahead of next year's local government elections. The ANC, which has hardly uttered a word about the Freedom ...
 Mail & Guardian Online1 week ago

Euro Slide Adds Fuel to Turnaround in European Earnings

European companies from Sanofi (SAN) to Deutsche Telekom AG stand to benefit this year as the euro's slump to a nine-year low against the dollar bolsters profit growth. While the slide reflects the weaker economic outlook in the 19-country euro ...
 BusinessWeek2 weeks ago Euro's Slide Adds Fuel to Turnaround in Europe Profit Growth  Washington Post2 weeks ago
[x]  

Sanofi/Regeneron's Zaltrap (Colorectal Cancer Pipeline Report) - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/gp57cs/zaltrap) has announced the addition of the "Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023" report to their offering. This report focuses on the current ...
 Individual.com2 weeks ago Research and Markets: Sanofi/Regeneron's Zaltrap (Colorectal Cancer Pipeline Report) - Forecast and Market Analysis to 2023  TMC Net2 weeks ago RESEARCH AND MARKETS : Sanofi/Regeneron's Zaltrap (Colorectal Cancer Pipeline Report) - Forecast and Market Analysis to 2023  4 Traders2 weeks ago China Insulin Market Review to 2018 - Increasing Focus on R&D Investments  Individual.com4 days ago
[x]  

Manitoba funds treatment with AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis

Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Jan. 16, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that the Manitoba Drug Program has included AUBAGIO(TM) (teriflunomide) 14 mg on the provincial drug ...
 Canada NewsWire1 week ago Nova Scotia funds treatment with AUBAGIO for Relapsing Remitting Multiple Sclerosis  Digital Journal2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less